Merck & Co ready to supplant Roche in oncologyMerck & Co could be ready to supplant Roche concerning oncology drugs, Les Echos reported on Thursday (p21).
Step in the fight against pancreatic cancer with LynparzaAstraZeneca/Merck & Co's oral PARP inhibitor Lynparza (olaparib) was shown in a Phase III trial to extend progression free survival (PFS) in patients with pancreatic cancer with BRCA1 or BRCA2 genetic mutation, Le Figaro (p12) and Les Echos (p21) reported on Tuesday (APMHE 63201).
Benefits of olanzapine in the treatment of cancer-related nauseaThe benefits of antipsychotic drug olanzapine for a new indication - cancer-related nausea -have been confirmed, according to two studies presented at ASCO, Le Figaro (p13) said on Wednesday.
Bayer to sell its animal health divisionBayer is in talks with various private equity firms bidding for its animal health division, Le Figaro reported on Tuesday (p27).
French homeopathy specialist Boiron prepares its defenceFrance's Boiron is preparing to defend the reimbursement of homeopathy to France's healthcare technology assessment body HAS later this month, reported Le Figaro (p27) on Thursday.
Aspen's French site growingSouth African group, Aspen, has increased its production of injectables, Le Monde reported, in its Wednesday's edition (p16).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.